Personalized mRNA cancer vaccines are the focus of a news article explaining trial developments and implications for tailored melanoma treatment strategies.
Key Takeaways
- Personalized mRNA vaccine added to pembrolizumab reduced melanoma recurrence in a phase III trial
- Vaccine is manufactured by sequencing each patient’s tumour to identify neoantigens
- Widespread use faces challenges because individualized vaccine design and manufacturing take several months